Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Response in relation to baseline anxiety levels in major depressive disorder treated with bupropion sustained release or sertraline.

Rush AJ, Trivedi MH, Carmody TJ, Donahue RM, Houser TL, Bolden-Watson C, Batey SR, Ascher JA, Metz A.

Neuropsychopharmacology. 2001 Jul;25(1):131-8.

2.

Do bupropion SR and sertraline differ in their effects on anxiety in depressed patients?

Trivedi MH, Rush AJ, Carmody TJ, Donahue RM, Bolden-Watson C, Houser TL, Metz A.

J Clin Psychiatry. 2001 Oct;62(10):776-81.

PMID:
11816866
3.

A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline.

Croft H, Settle E Jr, Houser T, Batey SR, Donahue RM, Ascher JA.

Clin Ther. 1999 Apr;21(4):643-58.

PMID:
10363731
4.

Does pretreatment anxiety predict response to either bupropion SR or sertraline?

Rush AJ, Batey SR, Donahue RM, Ascher JA, Carmody TJ, Metz A.

J Affect Disord. 2001 Apr;64(1):81-7.

PMID:
11292522
5.

Sexual dysfunction associated with the treatment of depression: a placebo-controlled comparison of bupropion sustained release and sertraline treatment.

Coleman CC, Cunningham LA, Foster VJ, Batey SR, Donahue RM, Houser TL, Ascher JA.

Ann Clin Psychiatry. 1999 Dec;11(4):205-15.

PMID:
10596735
6.
7.

Evaluation of sexual functioning in depressed outpatients: a double-blind comparison of sustained-release bupropion and sertraline treatment.

Segraves RT, Kavoussi R, Hughes AR, Batey SR, Johnston JA, Donahue R, Ascher JA.

J Clin Psychopharmacol. 2000 Apr;20(2):122-8.

PMID:
10770448
8.

Selecting among second-step antidepressant medication monotherapies: predictive value of clinical, demographic, or first-step treatment features.

Rush AJ, Wisniewski SR, Warden D, Luther JF, Davis LL, Fava M, Nierenberg AA, Trivedi MH.

Arch Gen Psychiatry. 2008 Aug;65(8):870-80. doi: 10.1001/archpsyc.65.8.870.

PMID:
18678792
9.

Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline.

Kasper S, Hajak G, Wulff K, Hoogendijk WJ, Montejo AL, Smeraldi E, Rybakowski JK, Quera-Salva MA, Wirz-Justice AM, Picarel-Blanchot F, Baylé FJ.

J Clin Psychiatry. 2010 Feb;71(2):109-20. doi: 10.4088/JCP.09m05347blu.

PMID:
20193645
10.

Fluoxetine versus sertraline and paroxetine in major depression: tolerability and efficacy in anxious depression.

Fava M, Rosenbaum JF, Hoog SL, Tepner RG, Kopp JB, Nilsson ME.

J Affect Disord. 2000 Aug;59(2):119-26.

PMID:
10837880
11.
12.

Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression.

Rush AJ, Trivedi MH, Wisniewski SR, Stewart JW, Nierenberg AA, Thase ME, Ritz L, Biggs MM, Warden D, Luther JF, Shores-Wilson K, Niederehe G, Fava M; STAR*D Study Team.

N Engl J Med. 2006 Mar 23;354(12):1231-42.

13.

Bupropion in the treatment of major depressive disorder in real-life practice.

Sennfelt DA, Marques da Silva MA, Tavares AP.

Clin Drug Investig. 2011 Oct 19;31 Suppl 1:19-24. doi: 10.2165/1159617-S0-000000000-00000.

PMID:
22015859
14.

Relative antidepressant efficacy of bupropion and the selective serotonin reuptake inhibitors in major depressive disorder: gender-age interactions.

Papakostas GI, Kornstein SG, Clayton AH, Soares CN, Hallett LA, Krishen A, Tucker VL.

Int Clin Psychopharmacol. 2007 Jul;22(4):226-9.

PMID:
17519646
15.

Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trials.

Thase ME, Haight BR, Richard N, Rockett CB, Mitton M, Modell JG, VanMeter S, Harriett AE, Wang Y.

J Clin Psychiatry. 2005 Aug;66(8):974-81.

PMID:
16086611
16.

Double-blind, placebo-controlled comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.

Hewett K, Gee MD, Krishen A, Wunderlich HP, Le Clus A, Evoniuk G, Modell JG.

J Psychopharmacol. 2010 Aug;24(8):1209-16. doi: 10.1177/0269881109106953. Epub 2009 Nov 25.

PMID:
19939870
17.

The efficacy and tolerability of bupropion in the treatment of major depressive disorder.

Moreira R.

Clin Drug Investig. 2011 Oct 19;31 Suppl 1:5-17. doi: 10.2165/1159616-S0-000000000-00000. Review.

PMID:
22015858
18.

Spotlight on sertraline in the management of major depressive disorder in elderly patients.

Muijsers RB, Plosker GL, Noble S.

CNS Drugs. 2002;16(11):789-94. Review.

PMID:
12383038
19.

Comparative sexual side effects of bupropion, fluoxetine, paroxetine, and sertraline.

Modell JG, Katholi CR, Modell JD, DePalma RL.

Clin Pharmacol Ther. 1997 Apr;61(4):476-87.

PMID:
9129565
20.

Combining serotonin reuptake inhibitors and bupropion in partial responders to antidepressant monotherapy.

Bodkin JA, Lasser RA, Wines JD Jr, Gardner DM, Baldessarini RJ.

J Clin Psychiatry. 1997 Apr;58(4):137-45.

PMID:
9164423
Items per page

Supplemental Content

Write to the Help Desk